Symbiox Investment & Trading Co Ltd

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid mixed financial metrics and peer comparisons, prompting investors to reassess the stock’s price attractiveness in the context of its historical performance and sector benchmarks.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite a challenging operational backdrop reflected in its financial metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a renewed price attractiveness relative to its historical and peer averages.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Sell, reflects evolving market perceptions and invites a closer examination of its price-to-earnings and price-to-book value metrics against historical and peer benchmarks.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating upgraded from Strong Sell to Sell as of 10 August 2026. This change reflects a nuanced shift in the company’s technical outlook, even as fundamental and financial trends remain subdued. The MarketsMOJO Mojo Score now stands at 31.0, signalling cautious investor sentiment amid persistent challenges in growth and profitability.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 3 August 2026. This shift reflects deteriorating technical indicators, stagnant financial performance, and persistent underperformance relative to market benchmarks, signalling heightened caution for investors.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating upgraded from Strong Sell to Sell as of 27 Jul 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges and valuation considerations.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 22 June 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and poor long-term growth prospects, signalling heightened caution for investors amid sustained underperformance relative to broader market benchmarks.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 June 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistently weak fundamental and financial trends. Despite the upgrade, the stock continues to face significant challenges, including poor long-term growth and underperformance relative to the broader market.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 10 June 2026. This shift reflects deteriorating technical indicators, stagnant financial performance, and weak long-term fundamentals, signalling heightened risks for investors amid a challenging market environment.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating upgraded from Strong Sell to Sell as of 5 June 2026. This change reflects a nuanced shift in the company’s technical outlook, even as its fundamental and financial trends remain subdued. The upgrade is primarily driven by improved technical indicators, while valuation and financial performance continue to pose challenges for investors.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has witnessed a notable shift in its valuation parameters, moving from a risky to an attractive valuation grade. This change, driven primarily by its price-to-book value and price-to-earnings ratio, signals a potential reappraisal of the stock’s price attractiveness despite ongoing challenges in profitability and market performance.

A sharp decline in Symbiox Investment & Trading Co Ltd has pushed the stock to a fresh 52-week low of Rs 1.36 on 6 Apr 2026, extending its downward trajectory amid broader market weakness and company-specific concerns.

For the second consecutive session, Symbiox Investment & Trading Co Ltd has extended its decline, hitting a fresh 52-week low of Rs 1.46 on 30 Mar 2026. This latest drop comes amid a broader sectoral weakness but also reflects company-specific pressures that have weighed heavily on the micro-cap NBFC’s shares.

Symbiox Investment & Trading Co Ltd’s stock price declined sharply to a fresh 52-week low of Rs.1.52 on 27 March 2026, marking a significant milestone in its ongoing downward trajectory. The stock underperformed both its sector and broader market indices, reflecting persistent challenges in its financial performance and market sentiment.

Symbiox Investment & Trading Co Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has touched a new 52-week low of Rs.1.56 today, marking a significant decline amid broader market weakness and persistent company-specific headwinds.

Symbiox Investment & Trading Co Ltd, a player in the Non Banking Financial Company (NBFC) sector, has reached a new 52-week low of Rs.1.63 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance concerns.